Landcent

About Landcent

Landcent is a social enterprise that develops and delivers solutions to combat diseases of poverty, with an initial focus on malaria. The company was founded in 2011 by Arun Prabhu and Huali (Danny) Lin. The inspiration came after Prabhu, during a business trip in 2010, attended the funeral of a four-year-old girl who had died from a mosquito bite, which catalyzed his decision to establish the company. Prabhu, now Executive Chairman, has a background in technical textiles and supply chain management and leads the company's vector control business. Landcent's European operations are headquartered in Schiphol-Rijk, Netherlands, and the company is led by CEO Justin Hays. The company operates on a model that addresses the full spectrum of care: prevention, diagnosis, and treatment. Its primary clients include governments, NGOs, and global health organizations operating in regions heavily affected by poverty-related diseases, with a significant focus on Sub-Saharan Africa, which accounts for the vast majority of global malaria cases. Landcent's business strategy involves a two-track approach: in the near-term, it aims to improve existing prevention technologies, and for the long-term, it focuses on discovering and developing new active compounds to combat insecticide resistance. A portion of its revenue is generated through "Sourcing as a Service," providing laboratory consumables and diagnostic kits, with profits reinvested into its R&D for malaria products. Landcent’s product portfolio is aligned with WHO recommendations for malaria control. Key products include insecticide-treated nets (ITNs) like Neonet®, which features a dual active ingredient design to fight insecticide resistance. The company also developed a patented microencapsulation technology that allows for the slow release of chemicals, extending the effectiveness of its nets and indoor residual sprays. In addition to prevention, Landcent is involved in treatment, offering antimalarial medications such as Codispaq® and Lansipar®, designed for children and pregnant women. The company is also expanding into diagnostics through a partnership with EASE-Medtrend to produce affordable, high-quality, and locally manufactured diagnostic tools for Sub-Saharan Africa. Since its inception, Landcent has achieved several key milestones. The company began discussions with the WHO in 2012, gained its first qualified products and patents in 2014, and became a member of the WHO's Global Collaboration for Development of Pesticides for Public Health (GCDPP) in 2017. Landcent has also established significant partnerships, including a joint laboratory with the Shanghai Institute of Organic Chemistry (SIOC) and has received multiple grants from the Bill & Melinda Gates Foundation to support its research into new active ingredients from natural compounds.